GRCE: the cashflow

MyFinsight

For the quarter ending 2025-12-31, GRCE had $1,810K increase in cash & cash equivalents over the period.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-12-31	2025-09-30	2025-06-30
Clinical development programs	124	-	-
Professional fees	870	-	-
Salaries and benefits	751	-	-
Stock-based compensation	109	-	-
Other general and administrative expenses	594	-	-
Other segment income	-38	-	-
Interest income, net	172	-	-
Tax benefits	0	-	-
Net loss	-2,314	-939	-3,362
Depreciation expense	3	0	2
Stock-based compensation	108	206	302
Change in fair value of derivative warrant liabilities	40	-1,427	487
Deferred income tax benefit	0	0	0
Receivables	0	0	-106
Prepaid expenses	103	-84	47
Trade and other payables	36	-1,067	711
Net cash used in operating activities	-2,230	-3,143	-1,801
Maturity of short-term investments	0	-	-
Purchase of short-term investments	0	0	0
Net cash used in investing activities	0	0	0
Proceeds from issuance of common stock from common warrant exercises	4,040	-	-
Payment of stock issuance costs	0	0	327
Net cash provided by financing activities	4,040	0	-327
Net decrease in cash and cash equivalents	1,810	-3,143	-2,128
Cash and cash equivalents at beginning of period	16,862	22,133	-
Cash and cash equivalents at end of period	18,672	16,862	-

Unit: Thousand (K) dollars